Zhi Tong Cai Jing·2026-02-03 07:49Group 1 - AstraZeneca announced a plan to invest $15 billion in China during the visit of the UK Prime Minister, showcasing the interest and recognition of multinational corporations (MNCs) in China's local R&D capabilities and market [1][2] - The investment aims to expand drug manufacturing and R&D, leveraging China's scientific strength and advanced manufacturing capabilities, as well as the collaboration advantages of the UK-China healthcare ecosystem [2] - This investment will significantly enhance AstraZeneca's capabilities in cell therapy and radiolabeled conjugates, supporting a diverse R&D pipeline for patients with cancer, blood diseases, and autoimmune disorders [3] Group 2 - The investment will be allocated to the establishment of global strategic R&D centers in Beijing and Shanghai, expansion of existing production bases in Wuxi, Taizhou, Qingdao, and Beijing, and the establishment of new production facilities [4] - AstraZeneca plans to expand its skilled workforce in China to over 20,000 employees [4]